Does high-dose extended course cyclophosphamide and methylprednisolone pulse therapy have a role in the management of systemic sclerosis-related interstitial lung disease?

Rheumatology (United Kingdom)

Volumn 55, Issue 12, 2016, Pages 2273-2275

  Abignano, Giuseppina ^a,b   Bissell, Lesley Anne ^a,b   Emery, Paul ^a,b   Del Galdo, Francesco ^a,b   Buch, Maya H ^a,b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; PREDNISOLONE; GLUCOCORTICOID;

CLINICAL ARTICLE; DIARRHEA; DISEASE CONTROL; DISEASE DURATION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG PULSE THERAPY; FATIGUE; FEMALE; HAIR LOSS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; LETTER; LEUKOPENIA; MAINTENANCE THERAPY; MALAISE; MALE; NAUSEA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYSTEMIC SCLEROSIS; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; COMBINATION DRUG THERAPY; COMPLICATION; DISEASE MANAGEMENT; MIDDLE AGED;

CYCLOPHOSPHAMIDE; DISEASE MANAGEMENT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES, INTERSTITIAL; MALE; METHYLPREDNISOLONE; MIDDLE AGED; SCLERODERMA, SYSTEMIC;

EID: 85019855308     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kew362     Document Type: Letter

References (8)

1. Kowal-Bielecka O, Landewé R, Avouac J et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009;68:620-8.
2. Tashkin DP, Elashoff R, Clements PJ et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-66.
3. Hoyles RK, Ellis RW, Wellsbury J et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006;54:3962-70.
4. Poormoghim H, Moradi Lakeh M, Mohammadipour M, Sodagari F, Toofaninjed N. Cyclophosphamide for scleroderma lung disease: a systematic review and metaanalysis. Rheumatol Int 2012;32:2431-44.
5. Bussone G, Mouthon L. Interstitial lung disease in systemic sclerosis. Autoimmun Rev 2011;10:248-55.
6. van den Hoogen F, Khanna D, Fransen J et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 2013;72:1747-55.
7. Jordan S, Distler JH, Maurer B et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis 2015;74:1188-94.
8. van Laar JM, Farge D, Sont JK et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 2014;311:2490-8.